SureTrader
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 1/17/2018 12:17:31 PM - Followers: 79 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

SureTrader
GALT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Statement of Changes in Beneficial Ownership (4) 01/17/2018 04:36:37 PM
GALT News: Statement of Changes in Beneficial Ownership (4) 01/17/2018 04:35:46 PM
GALT News: Statement of Changes in Beneficial Ownership (4) 01/17/2018 04:35:46 PM
GALT News: Current Report Filing (8-k) 01/04/2018 09:02:42 AM
GALT News: Current Report Filing (8-k) 12/19/2017 04:10:23 PM
PostSubject
#3286   Hear u This is still an amazing buy mjw007 01/17/18 12:17:31 PM
#3285   Crazy day...traders dream Selett 01/16/18 03:21:37 PM
#3284   Don't forget to mention Dr. Gil Omenn MD. rickyricks 01/15/18 12:12:48 PM
#3283   Two quotes from Dr Scott Friedman about trial biotech2010 01/14/18 07:51:17 PM
#3282   Nash only? Darwinian 01/11/18 11:01:49 PM
#3281   Conceptually, galectin has a job to do, if PeterKarol 01/10/18 08:46:22 PM
#3280   Hope you are right !! This company is a mjw007 01/08/18 03:29:53 PM
#3279   Such a Beauty europtiger 01/08/18 03:00:49 PM
#3278   Pfizer P1 Nash, Novartis, Gilead, BMY, ICPT. rickyricks 01/07/18 12:27:46 PM
#3277   San Francisco, CA is in the Presentation Title Tesla1 01/06/18 07:16:06 PM
#3276   The only smart thing you’ve said is “you KnokKnok 01/05/18 11:58:55 AM
#3275   It's interesting about the 2 mg dosage. I Darwinian 01/05/18 08:26:42 AM
#3274   I didn't 'turn on a dime', I said biotech2010 01/05/18 06:08:19 AM
#3273   you bought shares! Wow - that's equivalent Chess Master 01/05/18 02:39:28 AM
#3272   FWIW at this point, I came across this Darwinian 01/04/18 06:21:12 PM
#3271   What badders me why smaller dose works much Coolec78 01/04/18 05:25:07 PM
#3270   http://archive.fast-edgar.//20180104/AI2ZU22CZ22RB2Z2222C2WXKF4ANZZ22NSA2/ Th biotech2010 01/04/18 04:46:24 PM
#3269   The new 8K filing is supposedly for a thefamilyman 01/04/18 12:22:40 PM
#3268   You n me both... thefamilyman 01/03/18 12:01:04 AM
#3267   After all this time and effort, I hope Darwinian 01/02/18 11:00:18 PM
#3266   Thanks for posting This stock is a steal mjw007 12/29/17 02:44:57 PM
#3265   Nice! Maybe those January Call Options will thefamilyman 12/29/17 11:04:09 AM
#3264   Another article on GALT and Short FAKE news Chess Master 12/29/17 09:53:13 AM
#3263   It is now inhumane to knowingly give a rickyricks 12/24/17 06:51:48 PM
#3262   If your brokerage account can't afford to lose rickyricks 12/17/17 11:52:52 AM
#3261   Not necessarily. If they get partnership or buyout Coolec78 12/14/17 03:40:03 PM
#3260   The big problem is money. Who's going IRAHopeful 12/14/17 10:39:39 AM
#3259   I think that's incorrect. Darwinian 12/11/17 12:44:05 PM
#3258   I'm not sure what you mean? As I thefamilyman 12/11/17 12:07:41 PM
#3257   But the lower dose appeared to be more efficacious... Darwinian 12/10/17 12:18:07 PM
#3256   I think they need to increase the dosage thefamilyman 12/09/17 11:58:19 PM
#3255   GR MD 02 Phase 3!!! this drug rickyricks 12/09/17 11:51:51 AM
#3254   Wouldn't insiders have been better off to have Darwinian 12/08/17 05:28:26 PM
#3253   * * $GALT Video Chart 12-08-17 * * ClayTrader 12/08/17 04:19:16 PM
#3252   * * $GALT Video Chart 12-07-17 * * ClayTrader 12/07/17 05:24:56 PM
#3251   And then what, hire who? KnokKnok 12/06/17 02:15:58 PM
#3250   Crazy how quiet this board is before/after data CharlesHarvie 12/06/17 02:06:52 PM
#3249   Bouncing here bigblue72 12/05/17 10:30:44 AM
#3248   Should get a dead cat bounce here bigblue72 12/05/17 10:09:28 AM
#3247   Harrison just mentioned that combination therapy is the biotech2010 12/05/17 09:23:29 AM
#3246   Two words....Fire Traber! biotech2010 12/05/17 09:20:08 AM
#3245   GALT is paying the price for flying into fishhunter 12/05/17 09:13:31 AM
#3244   this needs to be part of a combination biotech2010 12/05/17 09:07:18 AM
#3243   Ouch Awl416 12/05/17 08:48:45 AM
#3242   Adam the odd fellow. I think he sokol 12/05/17 08:44:09 AM
#3241   Adam Feuerstein Tweets: $GALT study was total fail. davidsson10 12/05/17 08:40:44 AM
#3240   Missed the primary endpoint biotech2010 12/05/17 08:26:24 AM
#3239   Agreed How do u read that? mjw007 12/05/17 07:46:10 AM
#3238   Interesting - no PR yet - cc is Amatuer17 12/05/17 07:13:02 AM
#3237   I don’t know what will happen - AH Amatuer17 12/04/17 08:53:17 PM
PostSubject